Behzad Imani , Reza Safi-Ariyan , Babak Manaafi , Arezo Karampourian , Karim Ghazikhanlou Sani ,
Volume 72, Issue 4 (July 2014)
Abstract
Background: Platelet activation and aggregation plays an essential role in the for-mation of coronary artery thrombosis. Nowadays, the Clopidogrel is administered oral-ly as an inhibitor of platelet aggregation. Due to the high price of the original brand of Clopidogrel (Plavix), an Iranian brand of Clopidogrel (Osvix) has been produced. This study was conducted to evaluate the effectiveness, side effects and acceptability of lo-cally available brand of Osvix as anti platelet tablet in coronary artery bypass grafting patients in comparison to the original brand (Plavix) by means of platelet aggregation indexes.
Methods: This clinical study, was conducted at Heart Center of Ekbatan university Hospital in Hamadan in October 2011 to May 2012. In this study 80 patients undergo-ing coronary artery bypass grafting (CABG) were participated in two independent treatment groups. One group used the Iranian brand of Osvix and other one used the original brand (Plavix) as an inhibitor of platelet aggregation. To evaluate the effective-ness of these two in-inhibiting platelets regimens, blood samples were taken from the patients and platelet aggregation test was performed using Helena Biosiences Europe, PACKS4 aggrigometry system (made in France).
Results: Mean platelet-rich plasma amount for the Osvix and Plavix treatment group was 236.260 and 153.290 plt/µl respectively. Results showed a statistically significant difference in the rate of platelet-rich plasma by two above mentioned treatment groups. There was no observed statistical difference in side effects of two studied treatment groups. It must be noted that the effectiveness of Plavix tablet regimen as a platelet aggregation inhibitor in patients undergoing CABG was higher than the Osvix tablet treatment regimen.
Conclusion: This study showed the Iranian brand of Clopidogrel (Osvix) is significantly different from the original brand (Plavix) in terms of performance factors in preventing platelet aggregation in patients undergoing coronary artery bypass grafting.
